Mylan CEO Faces Calls to Explain 400% EpiPen Increase
Aug. 24 -- Members of Congress are in an unusual position as they demand an explanation for Mylan NV’s 400 percent price hike for the EpiPen and focus attention squarely on its CEO: Heather Bresch. Bloomberg's Toluse Olorunnipa reports on "Bloomberg Markets."
